June 22, 2011, 12:04 p.m. EDT
Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Number 7,964,563 for Prolactin
http://www.marketwatch.com/story/stem-cell-therapeutics-corp-announces-the-issuance-of-united-states-patent-number-7964563-for-prolactin-2011-06-22?reflink=MW_news_stmp
CALGARY, ALBERTA, Jun 22, 2011 (MARKETWIRE via COMTEX) -- Stem Cell Therapeutics Corp. /quotes/zigman/364225 CA:SSS -7.14% ("SCT" or the "Company") announces today that a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,964,563 was granted today. The patent is entitled, "Oligodendrocyte Precursor Cell Proliferation Regulated By Prolactin." Claims granted in this Stem Cell Therapeutics Corp/ Patent focus protecting the therapeutic use of Prolactin for Multiple Sclerosis.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows:
"We are very pleased by the granting of this patent, as it represents a cornerstone achievement in SCT's strategy to protect the use of prolactin for treating central nervous system disorders that involve white matter, and specifically for the treatment of Multiple Sclerosis. This patent builds upon the strong basic scientific evidence that prolactin possesses the ability to stimulate endogenous stem cells to increase oligodendrocytes precursor cells in animals with central nervous system injuries and importantly increase the amount of myelin in white matter lesions. The anticipated MS clinical trial for the prolactin development program will substantially advance SCT's understanding how this important, novel neuro-regenerative therapy affects recovery in MS patients."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company /quotes/zigman/364225 CA:SSS -7.14% focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as Stroke, traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Stem Cell Therapeutics Corp.
Allen Davidoff, PhD
CSO
403-245-5495 ext.226
adavidoff@stemcellthera.com
Stem Cell Therapeutics Corp.
Michael Cook
CFO
403-245-5495 ext.229
mcook@stemcellthera.com
www.stemcellthera.com
Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Number 7,964,563 for Prolactin
http://www.marketwatch.com/story/stem-cell-therapeutics-corp-announces-the-issuance-of-united-states-patent-number-7964563-for-prolactin-2011-06-22?reflink=MW_news_stmp
CALGARY, ALBERTA, Jun 22, 2011 (MARKETWIRE via COMTEX) -- Stem Cell Therapeutics Corp. /quotes/zigman/364225 CA:SSS -7.14% ("SCT" or the "Company") announces today that a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,964,563 was granted today. The patent is entitled, "Oligodendrocyte Precursor Cell Proliferation Regulated By Prolactin." Claims granted in this Stem Cell Therapeutics Corp/ Patent focus protecting the therapeutic use of Prolactin for Multiple Sclerosis.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows:
"We are very pleased by the granting of this patent, as it represents a cornerstone achievement in SCT's strategy to protect the use of prolactin for treating central nervous system disorders that involve white matter, and specifically for the treatment of Multiple Sclerosis. This patent builds upon the strong basic scientific evidence that prolactin possesses the ability to stimulate endogenous stem cells to increase oligodendrocytes precursor cells in animals with central nervous system injuries and importantly increase the amount of myelin in white matter lesions. The anticipated MS clinical trial for the prolactin development program will substantially advance SCT's understanding how this important, novel neuro-regenerative therapy affects recovery in MS patients."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company /quotes/zigman/364225 CA:SSS -7.14% focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as Stroke, traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Stem Cell Therapeutics Corp.
Allen Davidoff, PhD
CSO
403-245-5495 ext.226
adavidoff@stemcellthera.com
Stem Cell Therapeutics Corp.
Michael Cook
CFO
403-245-5495 ext.229
mcook@stemcellthera.com
www.stemcellthera.com